#USA #AbbVie #North Chicago #RINVOQ #Vitiligo

AbbVie Presents Long-Term RINVOQ® (upadacitinib) Findings in Non-Segmental Vitiligo

AbbVie has recently disclosed groundbreaking data from its Phase 3 studies, Viti-Up-1 and Viti-Up-2, concerning RINVOQ® (upadacitinib) in the treatment of non-segmental vitiligo (NSV). These studies, which stretched to week 76, exhibit not only sustained facial and overall body repigmentation but also advocate for the treatment's effectiveness when combined with narrowband ultraviolet B (NB-UVB) phototherapy.

Overview of RINVOQ® in Vitiligo Treatment

RINVOQ is the first and only systemic medication sanctioned in the European Union for managing non-segmental vitiligo in adult and adolescent patients aged 12 and older. As the disease often causes considerable psychological distress alongside visible symptoms, the need for effective long-term management strategies is essential. The findings from the recent studies not only underscore RINVOQ's role but also hint at promising avenues for its combined use with light therapy.

Results Highlights from the Studies

During the follow-up period, patients who continued treatment with RINVOQ (15 mg once daily) saw incremental increases in the rates of significant repigmentation measured by the Facial Vitiligo Area Scoring Index (F-VASI 75) and Total Vitiligo Area Scoring Index (T-VASI 50). Specifically, results showed an increase from 33.1% to 55.1% for F-VASI 75 and from 29.2% to 42.5% for T-VASI 50 in the Viti-Up-1 cohort, while in Viti-Up-2, the increases were from 27.6% to 47.4% and 26.2% to 40.1%, respectively, from week 48 to week 76.

Additionally, a phototherapy substudy outlined that combining RINVOQ with NB-UVB phototherapy resulted in even better outcomes compared to RINVOQ alone, further emphasizing the potential for combination therapies in managing NSV.

Significance of the Findings

Dr. Kori Wallace, AbbVie’s Vice President and Global Head of Immunology Clinical Development, stated, “Vitiligo is a chronic, unpredictable disease that can have a profound impact on patients’ lives. The substantial long-term data showcased provide hope for those affected by vitiligo, supporting the notion that RINVOQ can lead to significant repigmentation and improve patient quality of life.”

The data presented at the 2026 European Academy of Dermatology and Venereology Congress marks a pivotal moment for clinicians and patients alike, potentially allowing for a more comprehensive approach to vitiligo treatment. Dr. Julien Seneschal, a noted dermatologist, further commented on the findings, encouraging further exploration into combination approaches involving systemic JAK inhibitors like RINVOQ with phototherapy, which may enhance repigmentation for patients with NSV.

Safety Profile

The safety data remaining consistent with the established profile of RINVOQ, suggestive of no new safety signals, adds to the medication's robustness as a treatment option. Adverse events observed were primarily consistent with previous studies, highlighting the importance of monitoring patients but reassuring clinicians on the known tolerability of the drug.

Conclusion

The culmination of these findings positions RINVOQ as a promising systemic therapy for non-segmental vitiligo, paving the way for enhanced management strategies that integrate novel and innovative approaches. As AbbVie continues to lead in immunology and dermatology, their commitment to advancing healthcare through comprehensive research remains unwavering. The ongoing investigation into dual therapies signifies hope for better patient outcomes, substantial progress in the understanding of this often-challenging condition, and a future where those living with vitiligo can look forward to improved options.

For detailed updates, patients and healthcare professionals are encouraged to keep an eye on clinical trial websites and pharmacy resources as AbbVie continues to develop transformative therapies in dermatology.